A Guardian report reveals that Brexit is complicating and increasing costs for cancer clinical trials in the UK. Specifically, the eSMART trial, which involves targeted treatments for cancer-stricken youth, faces quadrupled import costs and delays due to new red tape. This is a result of Brexit-related requirements that are hindering collaboration between UK and EU researchers, causing patients in the UK to miss out on access to potentially life-saving treatments. Despite a charity's help in funding, significant challenges remain in launching innovative trials in Britain.
"Delaying QP release came at a cost of time and money, which could have been spent reaching more patients and offering them potentially transformative treatment. Children and young people with cancer cannot wait."
"The cost of importing medicines for the study...almost quadrupled from 52,000 to 205,000 because of Brexit. A range of factors were cited, including the expense of additional requirements in the paperwork for packaging, licensing and importation."
Collection
[
|
...
]